YouTube Agrees to Follow Australia’s New Under-16 Social Media Ban 
Trump Administration to Secure Equity Stake in Pat Gelsinger’s XLight Startup 
Hikvision Challenges FCC Rule Tightening Restrictions on Chinese Telecom Equipment 
Airline Loyalty Programs Face New Uncertainty as Visa–Mastercard Fee Settlement Evolves 
Tesla Expands Affordable Model 3 Lineup in Europe to Boost EV Demand 
Amazon Italy Pays €180M in Compensation as Delivery Staff Probe Ends 
Proxy Advisors Urge Vote Against ANZ’s Executive Pay Report Amid Scandal Fallout 
Sam Altman Reportedly Explored Funding for Rocket Venture in Potential Challenge to SpaceX 
Australia Moves Forward With Teen Social Media Ban as Platforms Begin Lockouts 
Microchip Technology Boosts Q3 Outlook on Strong Bookings Momentum 
Netflix’s Bid for Warner Bros Discovery Aims to Cut Streaming Costs and Reshape the Industry 
Anthropic Reportedly Taps Wilson Sonsini as It Prepares for a Potential 2026 IPO 
Firelight Launches as First XRP Staking Platform on Flare, Introduces DeFi Cover Feature 
IKEA Expands U.S. Manufacturing Amid Rising Tariffs and Supply Chain Strategy Shift 
Momenta Quietly Moves Toward Hong Kong IPO Amid Rising China-U.S. Tensions 
Visa to Move European Headquarters to London’s Canary Wharf 
NEW YORK, Dec. 01, 2015 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Osiris Therapeutics, Inc. (NASDAQ:OSIR) securities between May 12, 2014 and November 20, 2015.
Click here to learn about the case: http://docs.wongesq.com/OSIR-Info-Request-Form-1014. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period defendants issued false and misleading statements to investors and/or failed to disclose that: (1) Osiris improperly recognized revenue under contracts it had with its distributors; (2) Osiris’ disclosure controls and procedures were not effective as of December 31, 2014, March 31, 2015, and June 30, 2015; and (3) as a result, defendants’ statements about Osiris’ business and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
If you suffered a loss in Osiris Therapeutics you have until January 22, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://docs.wongesq.com/OSIR-Info-Request-Form-1014.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
